Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial.

@article{Hanash2012CardiovascularSO,
  title={Cardiovascular safety of one-year escitalopram therapy in clinically nondepressed patients with acute coronary syndrome: results from the DEpression in patients with Coronary ARtery Disease (DECARD) trial.},
  author={Jamal Abed Hanash and Baiba Hedegaard Hansen and J\orgen Fischer Hansen and Olav W. Nielsen and A Se K Rasmussen and Morten Birket-Smith},
  journal={Journal of cardiovascular pharmacology},
  year={2012},
  volume={60 4},
  pages={397-405}
}
BACKGROUND Selective serotonin reuptake inhibitors are commonly used for treatment of depression in patients with cardiac diseases. However, evidence of cardiovascular (CV) safety from randomized trials is based on studies of no longer than 6-month duration. We examined the CV safety of 1-year treatment with Selective serotonin reuptake inhibitor escitalopram compared with placebo in patients with recent acute coronary syndrome (ACS). METHODS The DECARD (DEpression in patients with Coronary… CONTINUE READING